The latest price target for Knight Therapeutics (OTCPK:KHTRF) was reported by Raymond James on March 6, 2024. The analyst firm set a price target for $7.50 expecting KHTRF to rise to within 12 months (a possible 102.45% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Knight Therapeutics (OTCPK:KHTRF) was provided by Raymond James, and Knight Therapeutics maintained their outperform rating.

There is no last upgrade for Knight Therapeutics

There is no last downgrade for Knight Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Knight Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Knight Therapeutics was filed on March 6, 2024 so you should expect the next rating to be made available sometime around March 6, 2025.

While ratings are subjective and will change, the latest Knight Therapeutics (KHTRF) rating was a maintained with a price target of $7.00 to $7.50. The current price Knight Therapeutics (KHTRF) is trading at is $3.70, which is out of the analyst’s predicted range.